|Mr. Matthew J. Pfeffer CPA||Chief Exec. Officer and Chief Financial Officer||N/A||N/A||59|
|Dr. David B. Thomson Ph.D., J.D.||Corp. VP, Gen. Counsel and Corp. Sec.||458.68k||424.8k||50|
|Dr. Raymond W. Urbanski M.D., Ph.D.||Chief Medical Officer and Corp. VP||501.32k||N/A||58|
|Dr. Michael E. Castagna Pharm.D.||Chief Commercial Officer and Corp. VP||378.41k||N/A||40|
|Ms. Rosabel Realica Alinaya||Principal Accounting Officer and Sr. VP of Fin.||N/A||N/A||56|
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Valencia, California.
MannKind Corporation’s ISS Governance QualityScore as of May 1, 2017 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 8.